Bevacizumab in Cervical Cancer: 5 Years After.

Authors

Krista S Pfaendler
Marisa C Liu
Krishnansu S Tewari, Division of Gynecologic Oncology, University of California Irvine, Orange, CA USA.Follow

Document Type

Article

Publication Date

7-1-2018

Publication Title

Cancer journal (Sudbury, Mass.)

Abstract

Over the past 5 years, addition of bevacizumab to combination chemotherapy for advanced, recurrent, and persistent cervical cancer has offered prolonged overall and progression-free survival. Since the original press release announcing the survival benefits of this antiangiogenesis therapy, there has been further study of bevacizumab related to quality of life, combination with other agents, use of imaging to evaluate likelihood of response, and development of biosimilars. This review summarizes publications related to bevacizumab use in advanced, recurrent, and persistent cervical cancer over the past 5 years since initial proof of concept of antiangiogenesis therapy and the initial dissemination of information regarding survival benefits of bevacizumab.

Clinical Institute

Women & Children

Clinical Institute

Cancer

Department

Obstetrics & Gynecology

Department

Oncology

Comments

KS Tewari is Tewari is affiliated with Providence St. Joseph Health, St. Joe Center for Cancer Prevention and Treatment.

Recommended Citation

Pfaendler, Krista S; Liu, Marisa C; and Tewari, Krishnansu S, "Bevacizumab in Cervical Cancer: 5 Years After." (2018). Articles, Abstracts, and Reports. 673.
https://digitalcommons.providence.org/publications/673